PDF(Pubmed)
Abstract：
UNASSIGNED: Azole antifungals are the most commonly used antifungals. The high use of azoles for long-term therapy and prophylaxis is prone to cause resistance. Thus, it is necessary to evaluate the antifungal activity against Candida albicans.
UNASSIGNED: Analyzing the comparison of antifungal exposure on the time-kill curve to Candida albicans.
UNASSIGNED: A case-control study was conducted with a posttest control group design. This study used Candida albicans clinical and ATCC isolates exposed to antifungal solutions with 1 ×, 4 ×, and 16 × minimum inhibitory concentrations (MIC). Antibiotics used included fluconazole, itraconazole, and voriconazole. Candida albicans isolates were incubated with MIC, and the number of colonies was counted at 0, 2, 4, 8, 12, 24, and 48 h. The number of colonies that grew every hour of observation was included in the time-kill curve. The data were then analyzed using an ANOVA test with p <0.05.
UNASSIGNED: The antifungals (fluconazole, itraconazole, and voriconazole) showed fungistatic activity against Candida albicans clinical and ATCC isolates. There was a significant comparison between the antifungal group and the control group at 12, 24, and 48 h. The most significant difference between antifungal and control group was found at 24 h where fluconazole had 95% CI = 0.807-2.061 (p <0.001), itraconazole 95% CI = 0.722-1.976 (p <0.001), and voriconazole CI 95% = 0.807-2.062 (p <0.001).
UNASSIGNED: Fluconazole, itraconazole, and voriconazole were effective in inhibiting the growth of Candida albicans. Maximum inhibition in vitro occurs after 12 h of antifungal exposure.
UNASSIGNED: Analyzing the comparison of antifungal exposure on the time-kill curve to Candida albicans.
UNASSIGNED: A case-control study was conducted with a posttest control group design. This study used Candida albicans clinical and ATCC isolates exposed to antifungal solutions with 1 ×, 4 ×, and 16 × minimum inhibitory concentrations (MIC). Antibiotics used included fluconazole, itraconazole, and voriconazole. Candida albicans isolates were incubated with MIC, and the number of colonies was counted at 0, 2, 4, 8, 12, 24, and 48 h. The number of colonies that grew every hour of observation was included in the time-kill curve. The data were then analyzed using an ANOVA test with p <0.05.
UNASSIGNED: The antifungals (fluconazole, itraconazole, and voriconazole) showed fungistatic activity against Candida albicans clinical and ATCC isolates. There was a significant comparison between the antifungal group and the control group at 12, 24, and 48 h. The most significant difference between antifungal and control group was found at 24 h where fluconazole had 95% CI = 0.807-2.061 (p <0.001), itraconazole 95% CI = 0.722-1.976 (p <0.001), and voriconazole CI 95% = 0.807-2.062 (p <0.001).
UNASSIGNED: Fluconazole, itraconazole, and voriconazole were effective in inhibiting the growth of Candida albicans. Maximum inhibition in vitro occurs after 12 h of antifungal exposure.
摘要：
未经授权：唑类抗真菌剂是最常用的抗真菌剂。用于长期治疗和预防的唑类的大量使用容易引起耐药性。因此，有必要评估针对白色念珠菌的抗真菌活性。
UNASSIGNED：分析白色念珠菌在时间-杀死曲线上抗真菌暴露的比较。
UNASSIGNED：采用试验后对照组设计进行病例对照研究。这项研究使用白色念珠菌临床和ATCC分离株暴露于1×抗真菌溶液，4×,和16×最小抑制浓度(MIC)。使用的抗生素包括氟康唑，伊曲康唑,和伏立康唑.白色念珠菌分离物与MIC孵育，并在0、2、4、8、12、24和48h计数菌落数。观察每小时生长的菌落数包括在时间-杀死曲线中。然后使用P<0.05的ANOVA检验分析数据。
未经授权：抗真菌药（氟康唑，伊曲康唑,和伏立康唑）对白色念珠菌临床和ATCC分离株具有抑菌活性。在12、24和48h时，抗真菌组和对照组之间存在显着比较。在24h时，发现抗真菌组和对照组之间的最显着差异，其中氟康唑的95％CI=0.807-2.061（p<0.001），伊曲康唑95%CI=0.722-1.976(p<0.001)，和伏立康唑CI95%=0.807-2.062（p<0.001）。
未经批准：氟康唑，伊曲康唑,伏立康唑可有效抑制白色念珠菌的生长。体外最大抑制发生在抗真菌暴露12小时后。
UNASSIGNED：分析白色念珠菌在时间-杀死曲线上抗真菌暴露的比较。
UNASSIGNED：采用试验后对照组设计进行病例对照研究。这项研究使用白色念珠菌临床和ATCC分离株暴露于1×抗真菌溶液，4×,和16×最小抑制浓度(MIC)。使用的抗生素包括氟康唑，伊曲康唑,和伏立康唑.白色念珠菌分离物与MIC孵育，并在0、2、4、8、12、24和48h计数菌落数。观察每小时生长的菌落数包括在时间-杀死曲线中。然后使用P<0.05的ANOVA检验分析数据。
未经授权：抗真菌药（氟康唑，伊曲康唑,和伏立康唑）对白色念珠菌临床和ATCC分离株具有抑菌活性。在12、24和48h时，抗真菌组和对照组之间存在显着比较。在24h时，发现抗真菌组和对照组之间的最显着差异，其中氟康唑的95％CI=0.807-2.061（p<0.001），伊曲康唑95%CI=0.722-1.976(p<0.001)，和伏立康唑CI95%=0.807-2.062（p<0.001）。
未经批准：氟康唑，伊曲康唑,伏立康唑可有效抑制白色念珠菌的生长。体外最大抑制发生在抗真菌暴露12小时后。
